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Abstract
Biological changes that occur during metastatic progression of breast cancer are still incompletely 
characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 
paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified 
using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate 
of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 
30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors 
converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to 
HER2-E tumors. We identified 47 genes that were expressed differentially in metastatic versus 
primary disease. Metastatic tumors were enriched for proliferation-related and migration-related 
genes and diminished for luminal-related genes. Expression of proliferation-related genes were 
better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic 
tissue rather than primary tissue. In contrast, a basal-like gene expression signature was better at 
predicting OSmet in primary disease compared with metastatic tissue. We observed correlations 
between time to tumor relapse and the magnitude of changes of proliferation, luminal B, or HER2-
E signatures in metastatic versus primary disease. Although the intrinsic subtype was largely 
maintained during metastatic progression, luminal/HER2-negative tumors acquired a luminal B or 
HER2-E profile during metastatic progression, likely reflecting tumor evolution or acquisition of 
estrogen independence. Overall, our analysis revealed the value of stratifying gene expression by 
both cancer subtype and tissue type, providing clinicians more refined tools to evaluate prognosis 
and treatment.
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Introduction
Despite new systemic treatment advances, metastatic breast cancer is still an incurable 
disease and a major cause of cancer-related death (1). Median overall survivals of patients 
with triple-negative, hormone receptor (HR)-positive/HER2-negative and HER2-positive 
diseases are approximately 12, approximately 20, and approximately 56 months, 
respectively (2–5). Thus, there is a need to better understand the biology behind the 
progression of tumor cells toward metastasis. To date, evidence suggests that both intrinsic 
properties of breast cancer cells and host organ microenvironment participate actively to this 
matter (6).
In general, detectable distant breast cancer metastases occur years, or even decades, after 
primary tumor diagnosis. These secondary lesions are believed to originate from 
disseminated tumor cells that underwent a period of dormancy (7). Tumor dormancy is the 
result of equal rates of cell proliferation and cell death (8). However, the molecular factors 
that promote the formation of detectable metastasis from disseminated tumor cells are 
largely unknown. To try to approach it, studies have started to identify the molecular 
differences between primary tumor and their matched metastatic lesions (9). At the DNA 
level, although significant differences have been observed, the vast majority (80%–85%) of 
molecular alterations are similar in both settings. For example, the discordance of HER2 
gene amplification by FISH in primary versus metastatic tissue is 3%–10% (10). Similarly, 
at the protein level, estrogen and progesterone receptors by IHC are discordant in 13%–28% 
of the cases (11). Overall, these results suggest that minor but important molecular changes 
occur during metastatic progression such as ESR1 mutations (12).
In terms of global gene expression, 4 main molecular subtypes [luminal A, luminal B, 
HER2-enriched (HER2-E) and basal-like], and a normal breast-like group, have been 
identified and intensively studied for the last 15 years in early breast cancer (13–16). Known 
as the “intrinsic subtypes of breast cancer,” these groups of tumors have revealed critical 
differences in incidence (17, 18), survival (19–21), and response to treatment (22, 23). 
Importantly, the information provided by the intrinsic subtypes complements and expands 
the information provided by classical clinical parameters (e.g., age, node status, tumor size, 
histologic grade) and pathologic markers [estrogen receptor (ER), progesterone receptor 
(PR), and HER2; refs. 24, 25], all of which are routinely used today in the clinic to stratify 
patients for prognostic predictions and to select treatments.
Recently, we evaluated the prognostic value of the intrinsic subtypes in 821 samples from a 
phase III clinical trial, where postmenopausal patients with metastatic HR+ breast cancer 
were treated with first-line letrozole ± lapatinib (26). The vast majority of samples (~80%) 
were from the primary tumor years before the patient relapsed. Interestingly, we observed 
that intrinsic subtype provided the largest amount of prognostic information in this setting 
beyond HER2 status, treatment, visceral disease, and other clinical–pathological variables. 
Overall, these results suggested that intrinsic subtype does not change substantially when 
recurrence occurs.
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Material and Methods
Study population
This retrospective study included nonconsecutive female patients over the age of 18 years 
with a histologic diagnosis of metastatic breast cancer detected at the time of diagnosis, at 
first relapse or after successive disease progressions. Tissues were collected from five 
independent sources: GEICAM/2009-03 ConvertHER trial (11), Hospital Clínico 
Universitario de Valencia, Vall d’Hebrón Institute of Oncology, University-AO Papardo and 
Hospital Clinic of Barcelona. To be included, samples were required to have a formalin-
fixed paraffin-embedded (FFPE) tissue sample from primary and metastatic tumor. Biopsies 
were performed by core biopsy or surgical process, according to the routine clinical practice 
of the hospitals. For each sample, receptor status (ER, PR, and HER2) were analysed at the 
local laboratory.
Gene expression analysis
All primary and metastatic tissues were analysed using the same methodology. A section of 
FFPE breast tissue was first examined with a hematoxylin and eosin staining to confirm the 
diagnosis and determine the tumour surface area. For RNA purification, three 10-μm FFPE 
slides were cut for each tumor, and macro-dissection was performed, when needed, to avoid 
normal breast contamination. A minimum of approximately 100 ng of total RNA was used 
to measure the expression of 105 breast cancer-related genes and 5 housekeeping genes 
(ACTB, MRPL19, PSMC4, RPLP0, and SF3A1) using the nCounter platform (Nanostring 
Technologies; ref. 27). Data was log base2–transformed and normalized using the 
housekeeping genes. Raw data have been deposited in the Gene Expression Omnibus under 
the accession number GSE92977.
Gene list
The list of 105 breast cancer–related genes includes genes from the following three 
signatures: PAM50 intrinsic subtype predictor (n = 50; ref. 28), claudin-low subtype 
predictor (n = 43; ref. 29), VEGF/Hypoxia signature (n = 13; ref. 30). In 8 addition, we 
included individual genes that have been found to play an important role in breast cancer 
[i.e., CD24 (29), CRYAB (31), ERBB4 (32), PIK3CA (13), PTEN (13), RAD17 (33), 
RAD50 (33), and RB1 (13)]. The complete list of genes can be found in Supplementary 
Table S1.
Intrinsic subtype
All tumors were assigned to an intrinsic molecular subtype of breast cancer (luminal A, 
luminal B, HER2-E, and basal-like) and the normal-like group using the previously reported 
PAM50 subtype predictor (28).
Claudin-low intrinsic subtype
We applied the previously reported 9-Cell line claudin-low predictor (29). A sample was 
identified as claudin-low independently of the PAM50 subtype call, as previously reported.
Cejalvo et al. Page 4
Cancer Res. Author manuscript; available in PMC 2018 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gene signatures
The expression of 10 independent signatures was evaluated as a continuous variable. The 
PAM50 predictor calculates, for each sample, the correlation coefficient to each of the 5 
PAM50 centroids (luminal A, luminal B, basal-like, HER2-enriched, and normal-like). Each 
centroid was considered a single signature. In addition, the PAM50 predictor outputs a risk 
of recurrence (ROR) score at 10 years. The ROR score based on subtype (ROR-S) and 
subtype and proliferation (ROR-P) were developed in a micro-array-based cohort of node-
negative, untreated early breast cancer (34). In addition, we evaluated the following three 
signatures: proliferation score, which is the mean expression of 11 proliferation-related 
genes (21), VEGF/Hypoxia signature (30), which is the mean expression of 13 hypoxia-
related genes, and claudin-low signature (as a continuous variable; ref. 29).
Statistical analysis
χ2 tests were performed to determine the differences in the distribution of variables. To 
identify genes whose expression was significantly different between paired primary and 
metastatic samples, we used a paired two-class significance of microarrays (SAM) with a 
false discovery rate (FDR) <5% (35). Biologic analysis of gene lists was performed with 
DAVID annotation tool (http://david.abcc.ncifcrf.gov/; ref. 36). Time to tumor recurrence 
(TTR) was defined as the period of time from surgery to the date of the first distant relapse. 
Overall survival from metastatic disease (OSmet) was defined as the period of time of 
metastatic disease to death or last follow-up. Estimates of survival were from the Kaplan–
Meier curves and tests of differences by the log-rank test. Univariate Cox models were used 
to test the independent prognostic significance of each variable. All statistical computations 
were carried out in R v2.15.1 (http://cran.r-project.org). All statistical tests were two sided, 
and the statistical significance level was set to less than 0.05.
Results
Clinical–pathologic characteristics
A total of 123 patients were included (Supplementary Table S2). The median age at breast 
cancer diagnosis was 52.5 years (range, 28–90). In primary disease, the 
immunohistochemical analyses showed 73.17% (n = 90) of patients had HR-positive (HR+), 
15.45% (n = 19) HER2-positive (HER2+), and 9.76% (n = 12) triple-negative disease. In 
metastatic disease, 69.92% (n = 86) of patients had HR+, 19.51% (n = 24) HER2+, and 
9.76% (n = 12) triple-negative disease. No significant differences (P > 0.502) were observed 
in the distribution of the three IHC groups in primary versus metastatic disease. Fourteen 
patients (11.38%) presented with de novo metastatic disease. Median follow-up and OSmet 
were 76.5 and 84 months, respectively (Supplementary Fig. S1).
Type of metastatic tissues
The organs of origin of the metastatic biopsies analysed in this study were skin (n = 35; 
28.4%), lymph nodes (n = 24; 19.5%), liver (n = 20; 16.3%), bone (n = 16; 13%), lung (n = 
7; 5.7%), ovarian and peritoneum (n = 7; n = 5.7%), pleural (n = 6; 4.9%) and others (n = 8; 
6.5%), including brain, pericardial fluid, and colon metastases (Supplementary Fig. S2).
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Subtype distribution
The distribution of the PAM50 intrinsic subtype classification in primary tumor versus 
metastatic disease was 39% versus 26% for luminal A (P = 0.029), 26% versus 35.8% for 
luminal B (P = 0.097), 11.4% versus 22% for HER2-E (P = 0.026) and 9.8% versus 12.2% 
for basal-like tumors (P = 0.540; Fig. 1). Individually, subtype concordance was high for 
basal-like (100%), HER2-E (76.9%), and luminal B (70.0%) tumors (Table 1). Regarding 
luminal A primary tumors, 44.7% remained luminal A in the metastasis, switching to 
luminal B in 40.4% and HER2-E in 14.9% of the cases. Overall, primary luminal tumors (A 
and B combined) changed to a HER2-E in 14.28%, despite 81% of them being clinically 
HER2 negative. Cohen kappa coefficient was 0.38 [95% confidence interval (CI), 0.27–0.5, 
P < 0.001]. These results were not affected when the claudin-low classification was 
investigated as no claudin-low tumor was identified in this series. Finally, we observed that 
liver and lung metastases showed the highest and lowest subtype conversion rate (75% and 
14%), respectively. However, these results by site of metastasis need further validation due 
to the small sample sizes (Supplementary Table S3).
Expression changes of individual signatures
We evaluated the expression changes of each individual signature between primary and their 
metastatic samples. Luminal A and normal-like signatures were found significantly less 
expressed in metastatic tumors than in primary tumor (Fig. 2). In contrast, luminal B, HER2-
E, and proliferation signatures were found more expressed in metastatic tumors than in 
primary tumors. Finally, the expression of basal-like, VEGF/hypoxia and claudin-low 
signatures was similar between primary and metastatic disease (Fig. 2).
Expression changes of individual genes
Among 105 breast cancer–related genes, 16 and 31 genes were found up- and downregulated 
in metastatic tissues compared with primary tissues (FDR < 5%; Table 2). The upregulated 
gene list was enriched for genes involved in survival and migration (e.g., FGFR4), cell cycle 
(e.g., CDC6 and CCNB1), and DNA repair (e.g., TYMS). The downregulated gene list was 
enriched for genes involved in response to hormone stimulus (e.g., BCL2 and PGR; Fig. 2), 
differentiation (e.g., GATA3) and chromatin regulation (e.g., CXXC5).
A similar analysis was performed within each of the subtypes identified in primary disease. 
Concordant with the subtype changes, 25, 8, 7, and 0 genes were found differentially 
expressed in luminal A, luminal B, HER2-E, and basal-like primary disease, respectively, 
compared with metastatic disease (Supplementary Table S4).
Association with overall survival
We evaluated the ability of the 10 signatures to predict OSmet in primary (Fig. 3A) versus 
metastatic (Fig. 3B) disease. Interestingly, no signature consistently predicted OSmet in both 
primary and metastatic disease. In primary disease, basal-like signature was found 
associated with worse outcome (HR = 1.50, P = 0.007), while the VEGF/Hypoxia signature 
was associated with a better outcome (HR = 0.65, P = 0.016). In metastatic disease, 
proliferation was found associated with worse outcome (HR = 1.40, P = 0.047).
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These results suggested that OSmet might be better predicted by measuring either the 
primary tumor or the metastatic tumor depending on the biological process (e.g., 
proliferation) being evaluated. To further explore this, we evaluated the ability of each 
individual gene to predict OSmet in primary versus metastatic disease. Among 105 genes, 
14 and 10 genes were found associated with OSmet in primary and metastatic disease, 
respectively. Interestingly, only one gene (GATA3) consistently predicted favorable outcome 
in both settings (Fig. 4). In primary disease, high expression of 13 of the 14 genes was found 
associated with better outcome. These 13 genes (e.g., PGR, ESR1, and FOXA1) were 
mostly tracking luminal-related biological processes. On the contrary, high expression of 8 
of the 10 genes in metastatic disease was found associated with worse outcome. These 8 
genes (e.g. MYC, CCNE1, and CCNB1) were mostly tracking cell cycle/proliferation-
related biological processes.
Finally, we explored the ability of each gene signature to predict OSmet in patients with 
tumors with no subtype conversion (n = 59) versus patients with tumors without subtype 
conversion (n = 49). The results revealed that in patients with no subtype conversion, the 
associations of signatures with OSmet were very similar when the primary or the metastatic 
tumors were evaluated. In patients with subtype conversion, the associations of signatures 
with OSmet were generally different when the primary or the metastatic tumors were 
evaluated. Among them, the HER2-E signature was found significantly associated with poor 
outcome (HR = 1.86, P = 0.046) when evaluated in metastatic tumors but not when 
evaluated in primary disease (Supplementary Fig. S3).
Magnitude of gene expression changes versus TTR
To evaluate if the gene expression changes observed in metastatic tissues are a reflection of 
tumor evolution over time, we plotted the magnitude of change of the expression of each 
signature versus TTR (Fig. 5). The results revealed a positive correlation between TTR and 
HER2-E (corr = 0.324, P < 0.001), luminal B (corr = 0.27, P = 0.004), Proliferation score 
(corr = 0.291, P = 0.002), and ROR-P (corr = 0.295, P = 0.001). In contrast, normal-like and 
luminal A signatures showed a negative correlation with TTR (corr = −0.285, P = 0.002; 
corr = −0.219, P = 0.019, respectively).
Gene-by-gene analysis revealed a positive correlation between TTR and the magnitude of 
change of genes implicated in cell proliferation (CEP55: corr = 0.244, P = 0.024), 
mitogenesis, and differentiation biological process (FGFR4: corr = 0.211, P = 0.044). In 
contrast, a negative correlation was observed with genes that participate in cell-to-cell 
adhesion (CLDN4: corr = −0.207, P = 0.027; F11R: corr = −0.237, P = 0.01), regulation of 
DNA damage repair (RAD17: corr: −0.226, P = 0.017), tumor suppression (GRHL2: corr = 
−0.186, P = 0.05), mammary gland development (PGR: corr = −0.203, P = 0.045), and that 
attenuate cell migration (ESRP1: corr = −0.252, P = 0.006).
Discussion
Here, we explored RNA-based expression differences between paired primary and 
metastatic breast tumors and made the following observations: (i) intrinsic molecular 
subtype is largely maintained during metastatic recurrence, except for luminal A disease, 
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which converted to luminal B and HER2-enriched in 55% of the cases; (ii) metastatic tissues 
show higher expression of proliferative and lower expression of luminal-related genes 
compared to primary tumors, except for basal-like disease, which seems to be very stable 
from a RNA-based perspective; (iii) different biological processes can predict overall 
survival from recurrence when evaluated in primary versus metastatic disease; (iv) an 
intriguing relationship seems to exist between the time taken to develop detectable 
metastases and the aggressiveness of the tumor, indicating that a tumor might evolve towards 
a more aggressive phenotype as time evolves.
Previous studies have evaluated the rates of change of the three classical pathologic 
biomarkers (i.e., ER, PR, and HER2) between primary and metastatic tumors (37, 38). 
Overall, the rates of ER, PR, and HER2 conversion were 13%, 28%, and 3%–10%, 
respectively (11). Among the three genes, we also observed PGR as the top downregulated 
gene in metastatic compared with primary tissues. Nonetheless, the three classical 
biomarkers are largely maintained in the metastatic setting, which is concordant with our 
findings using the basal-like, HER2-enriched, and luminal A/B intrinsic subtype 
classification. At the same time, prior gene expression-based studies with smaller number of 
patients are concordant with our findings (39–41). However, Lee and colleagues evaluated 
the PAM50 intrinsic subtypes in 17 paired samples of primary and brain metastasis, and 
subtype conversion was observed in 47.1% of the cases, which is higher than the 30.9% 
conversion rate observed in our study. However, similar to our study, a large proportion of 
luminal A primary tumors (1/6) changed to non-luminal A disease, and all basal-like 
primary tumors (n = 6) remaining basal-like at recurrence (42).
Other studies have evaluated changes in somatic mutations and gene copy-number 
aberrations (CNA) between primary and metastasis. For example, Meric-Bernstam and 
colleagues (43) performed targeted DNA sequencing of 3,320 exons of 182 cancer-related 
genes plus 37 introns from 14 genes in 74 tumors. In 33 matched primary and recurrent 
tumors, 97 of 112 (86.6%) somatic mutations were concordant. Of identified CNAs, 136 of 
159 (85.5%) were concordant. There was an increased frequency of CDK4/MDM2 
amplifications in recurrences, as well as gains and losses of other actionable alterations. The 
authors concluded that analysis of recurrent tumors before treatment may provide additional 
insights, as both gains and losses of targets are observed. In another study, Ding and 
colleagues (41) described the genomic analyses of four DNA samples from an African-
American patient with basal-like breast cancer: peripheral blood, the primary tumor, a brain 
metastasis, and a xenograft derived from the primary tumor. Of the 50 validated point 
mutations and small indels, 48 were detectable in all three tumors. Overall, while additional 
somatic mutations, copy number alterations, and structural variations occurred during the 
clinical course of the disease, most of the original mutations and structural variants present 
in the primary tumor were propagated.
Similar to prior studies looking at DNA alterations, we did not identify large absolute 
expression changes at the RNA level between primary and metastatic disease. Nonetheless, 
47 genes were found differentially expressed, mostly within luminal A/B disease. Among 
them, FGFR4 was detected as the top upregulated gene in metastatic disease. Interestingly, 
this gene is found in the PAM50 gene list and its overexpression is characteristic of the 
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HER2-E intrinsic subtype. Fibroblast growth factor receptors are involved in development, 
differentiation, cell survival, migration, angiogenesis and carcinogenesis (44). Dimerization 
of the receptor leads to intracellular phosphorylation of receptor kinase domains and 
intracellular signal transduction, including RAS/RAF/MEK and PI3K/AKT pathways (45). 
These evidences suggest that FGFR4 could drive the HER2-E phenotype in metastatic 
lesions with a HER2-negative/HER2-E profile. Indeed, we observed that the 8 patients 
whose tumors changed from luminal A/B in primary disease to HER2-E in metastasic 
disease showed an increase in FGFR4 expression but not ERBB2 expression 
(Supplementary Fig. S4). Of note, HER2-E subtype has been associated with estrogen-
independent growth and poor outcome in patients with HR+/HER2-negative breast cancer 
treated with anti-estrogens (46, 47). Further mechanistic studies are needed to elucidate the 
role of FGFR4 in metastatic disease.
Currently, large-phase III clinical trials, especially within HR+/HER2-negative disease, are 
not taking into account this biological heterogeneity, such as proliferation, which is not well 
captured by HR and HER2 statuses. For example, patients with a luminal A profile 
following endocrine therapy might be treated with second-line endocrine therapy while those 
that change to a HER2-negative/HER2-E or luminal B profile might be treated with 
chemotherapy or other novel combinatory strategies such as endocrine therapy and CDK4/6 
inhibition. Overall, this result suggests that, although there is some stability of the intrinsic 
subtype, approximately 40% of the tumors will change subtype, highlighting the need to 
biopsy metastatic disease to better understand the clinical and biological evolution of a 
tumor.
Another interesting observation was the significant correlation between the magnitude of 
gene expression changes of various signatures between primary and metastasis disease and 
the time from diagnosis to tumor recurrence. Specifically, we observed that the longer the 
time to recurrence, the more aggressive the tumors become based on proliferation and 
expression of luminal genes. This suggests that there is an intrinsic evolution of tumor cells 
towards a more aggressive phenotype as time elapses. However, the correlation coefficients 
were weak and thus the magnitude of gene expression changes might also be explained by 
other variables such as the treatments received in (neo)adjuvant setting.
This study has several limitations worth noting. First, this is a retrospective study using 
tumor samples from different hospitals and a selection bias is plausible. Second, patients 
received different adjuvant and/or metastatic systemic treatments and thus we could not 
evaluate treatment effects on tumor biology or survival. However, subtype conversion of the 
14 patients with de novo metastatic disease was found to be 57.1%, suggesting that subtype 
conversion is independent of treatment effects. More studies are needed to address this 
particular question. Third, metastatic tumor biopsies were not always collected at the time of 
the diagnosis of recurrent disease. Fourth, we did not analyze DNA mutations such as ESR1 
whose incidence is known to increase during tumor progression (12). Further studies will be 
able to evaluate if the gene expression changes observed during progression of luminal 
breast cancer are related to the appearance of ESR1 mutations.
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To conclude, most biological changes occurring during metastatic progression of breast 
cancer are largely unknown today. Here, we compared intrinsic molecular subtype and 
expression of individual genes in paired primary and metastatic tissues. Our results suggest 
that although intrinsic subtype is largely maintained during metastatic progression, luminal/
HER2-negative tumors acquire a luminal B or HER2-E profile during metastatic 
progression, likely reflecting tumor evolution and/or acquisition of estrogen-independency. 
Moreover, our study highlights the importance of molecular characterization of metastatic 
disease.
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Figure 1. 
Distribution of intrinsic subtype in primary versus metastatic disease.
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Figure 2. 
Gene and signature expression changes between primary and metastasis. P value was 
obtained after performing a paired t test.
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Figure 3. 
Association of 10 signatures with OSmet when evaluated in primary (A) and metastatic (B) 
disease. Each signature was evaluated as a continuous variable and was standardized to have 
a mean of 0 and a SD of 1. The size of the square is inversely proportional to the SE; 
horizontal bars represent the 95% Cls of HRs. Statistically significant variables are shown in 
blue. Each gene signature was evaluated in a univariate analysis.
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Figure 4. 
Venn diagram of genes that predict overall survival from the data of recurrence when 
analyzed in primary versus metastatic disease. Green, genes associated with good prognosis; 
red, genes associated with poor prognosis.
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Figure 5. 
Correlation between time to tumor recurrence (TTR) and the magnitude of gene/signature 
expression changes between primary and metastatic disease.
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Table 2
List of up- and downregulated genes differentially expressed between metastatic versus primary disease across 
all samples (FDR<5%)
Gene name Gene symbol Score (d) Fold change FDR (%)
Fibroblast growth factor receptor 4 FGFR4   3.38   1.74 0
Cell division cycle 6 CDC6   2.14   1.29 1.90
Maternal embryonic leucine zipper kinase MELK   1.99   1.27 1.90
Pituitary tumor-transforming PTTG1   1.80   1.21 1.90
Cell division cycle 20 CDC20   1.79   1.23 1.90
Thymidylates synthetase TYMS   1.75   1.22 1.90
Centrosomal protein CEP55   1.73   1.24 1.90
Cyclin B1 CCNB1   1.71   1.19 1.90
Phosphoglycerate dehydrogenase PHGDH   1.69   1.23 1.90
Keratin 8, Type II KRT8   1.68   1.17 1.90
Ribonucleotide reductase M2 RRM2   1.67   1.22 1.90
Epithelial cell adhesion molecule EPCAM   1.50   1.15 3.60
BCL2-Associated athanogene BAG1   1.42   1.14 3.60
Ubiquitin-conjugating enzyme E2T UBE2T   1.38   1.17 4.82
V-Myb myeloblastosis viral oncogene homolog-like 2 MYBL2   1.36   1.21 4.82
Serine Peptidase Inhibitor, Kunitz Type, 2 SPINT2   1.33   1.13 4.82
Transmembrane protein 158 TMEM158 −6.29 −1.34 0
Keratin 17, Type I KRT17 −5.55 −1.22 0
Matrix metallopeptidase 11 MMP11 −5.39 −1.32 0
Secreted frizzled-related protein 1 SFRP1 −4.26 −1.39 0
Zinc finger E-box binding homeobox 1 ZEB1 −4.19 −1.57 0
Progesterone receptor PGR −3.72 −1.40 0
Crystallin, alpha B CRYAB −2.90 −1.59 0
Melanoma inhibitor activity MIA −2.82 −1.55 0
V-Myc myelocytomatosis viral oncogene homolog MYC −2.69 −1.67 0
N-Acetyltransferase 1 NAT1 −2.31 −1.62 0
Microtubule-associated protein tau MAPT −2.25 −1.64 0
Estrogen receptor ESR1 −2.07 −1.65 0
Retinoid-inducible nuclear factor CXXC5 −2.07 −1.80 0
Fibrilin 1 FBN1 −1.99 −1.72 0
AXL receptor tyrosine kinase AXL −1.88 −1.78 0
Forkhead box A1 FOXA1 −1.87 −1.72 0
Solute carrier family 16 SLC16A3 −1.82 −1.78 0
Lipoma HMGIC fusion partner LHFP −1.74 −1.78 0
Solute carrier family 39 member 6 SLC39A6 −1.73 −1.75 0
Caveolin 1 CAV1 −1.59 −1.78 0
GATA binding protein 3 GATA3 −1.54 −1.79 0
Erb-B2 receptor tyrosine kinase 2 ERBB2 −1.52 −1.82 0
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Gene name Gene symbol Score (d) Fold change FDR (%)
B-Cell CLL/Lymphoma 2 BCL2 −1.41 −1.80 1.35
DNA damage inducible transcript 4 DDIT4 −1.17 −1.85 3.60
Claudin 7 CLDN7 −1.10 −1.87 3.60
Cadherin 3 CDH3 −1.10 −1.82 3.60
Adrenomedullin ADM −1.07 −1.83 4.82
Phosphatase and tensin homolog PTEN −1.06 −1.91 4.82
Forkhead Box C1 FOXC1 −1.03 −1.82 4.82
MET proto-oncogene, receptor tyrosine kinase MET −1.02 −1.83 4.82
Vimentin VIM −0.99 −1.88 4.82
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